Uniseed and the Australian government-backed MRCF have invested $18.5m in kidney disease drug developer Certa
Certa Therapeutics, a Australia-based precision medicine developer that counts biopharmaceutical company Shire as an investor, has raised A$25m ($18.5m) in its latest funding round.
The capital was provided by the Medical Research Commercialisation Fund (MRCF), which invested $16.3m on behalf of the Australian government’s Biotechnology Translation Fund, and multi-university venture capital fund Uniseed, which supplied the rest.
Certa Therapeutics is developing precision therapies for kidney disease that is caused by tissue thickening and scarring known as fibrosis. The condition can…
